Today, Fool.com health-care analysts David Williamson and Brenton Flynn look at Sarepta's nearly 200% share-price jump recently.
The company had some very favorable results with its revolutionary cystic fibrosis drug, and though it's only positioned to capture a small slice of the market currently, the potential to develop similar drugs that would target a larger patient population is enormous. The company could go even higher from here without such developments as well, as both Brenton and David see it as a reasonable buyout candidate. Even after the pop, it may still have room to run.
When it comes to do-or-die businessea, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.
RSS Headlines
Fool UK
Comments from our Foolish Readers
Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the
Report this Comment icon found on every comment.
Report this Comment On October 04, 2012, at 5:58 AM, jemstone75 wrote:
It was a very exciting day for me, a stockholder. However, the drug in question is for a rare form of Muscular Dystrophy. Maybe there is another study for Cystic Fibrosis? In any case, to help these children is awesome and could lead to progress with MS.
Add your comment.